Cochrane · systematic review · CD009120
Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients
Zhang, L, Zeng, X, Fu, P, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
30
current version
GRADE rated
30
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 5 · 16.7%Moderate 25 · 83.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Angiotensin receptor blockers (ARBs) versus conventional therapy for preserving residual kidney function in peritoneal dialysis patients
Population: patients receiving PD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Residual kidney function (3 months) Angiotensin receptor blockers (ARBs) vs conventional therapy | no estimate extracted | 1 study · 44 participants | Moderate |
Residual kidney function (6 months) Angiotensin receptor blockers (ARBs) vs conventional therapy | no estimate extracted | 1 study · 44 participants | Moderate |
Residual kidney function (≥ 12 months) Angiotensin receptor blockers (ARBs) vs conventional therapy | no estimate extracted | 3 studies · 110 participants | Moderate |
Residual kidney function (12 months) Angiotensin receptor blockers (ARBs) vs conventional therapy | no estimate extracted | 1 study · 44 participants | Moderate |
Residual kidney function (24 months) Angiotensin receptor blockers (ARBs) vs conventional therapy | no estimate extracted | 2 studies · 66 participants | Moderate |
Urinary protein excretion Angiotensin receptor blockers (ARBs) vs conventional therapy | no estimate extracted | 2 studies · 66 participants | Low |
Kt/V Angiotensin receptor blockers (ARBs) vs conventional therapy | no estimate extracted | 2 studies · 76 participants | Moderate |
Weekly creatinine clearance Angiotensin receptor blockers (ARBs) vs conventional therapy | no estimate extracted | 3 studies · 110 participants | Low |
Systolic BP Angiotensin receptor blockers (ARBs) vs conventional therapy | no estimate extracted | 3 studies · 110 participants | Moderate |
Diastolic BP Angiotensin receptor blockers (ARBs) vs conventional therapy | no estimate extracted | 3 studies · 110 participants | Moderate |
Serum potassium Angiotensin receptor blockers (ARBs) vs conventional therapy | no estimate extracted | 1 study · 44 participants | Low |
Adverse events (episodes of peritonitis) Angiotensin receptor blockers (ARBs) vs conventional therapy | RR 0.67 [0.18, 2.54] | 1 study · 34 participants | Low |
Angiotensin‐converting enzyme inhibitors (ACEi) versus conventional therapy for preserving residual kidney function in peritoneal dialysis patients
Population: patients receiving PD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Decline in residual kidney function (12 months) Angiotensin‐converting enzyme inhibitors (ACEi) vs conventional therapy | no estimate extracted | 1 study · 60 participants | Moderate |
Anuria Angiotensin‐converting enzyme inhibitors (ACEi) vs conventional therapy | RR 0.32 [0.11, 0.94] | 1 study · 60 participants | Moderate |
Mortality Angiotensin‐converting enzyme inhibitors (ACEi) vs conventional therapy | RR 1.5 [0.27, 8.34] | 1 study · 60 participants | Moderate |
Cardiac events Angiotensin‐converting enzyme inhibitors (ACEi) vs conventional therapy | RR 1 [0.37, 3.21] | 1 study · 60 participants | Moderate |
Cardiac events (fatal) Angiotensin‐converting enzyme inhibitors (ACEi) vs conventional therapy | RR 1 [0.15, 6.64] | 1 study · 60 participants | Moderate |
Cardiac events (non fatal) Angiotensin‐converting enzyme inhibitors (ACEi) vs conventional therapy | RR 1 [0.31, 3.27] | 1 study · 60 participants | Moderate |
Adverse events (episodes of peritonitis) Angiotensin‐converting enzyme inhibitors (ACEi) vs conventional therapy | RR 1.13 [0.47, 2.71] | 1 study · 60 participants | Moderate |
Adverse events (episodes of peritonitis) ‐ treated with an aminoglycoside Angiotensin‐converting enzyme inhibitors (ACEi) vs conventional therapy | RR 1.2 [0.41, 3.51] | 1 study · 60 participants | Moderate |
Adverse events (episodes of peritonitis) ‐ not treated with an aminoglycoside Angiotensin‐converting enzyme inhibitors (ACEi) vs conventional therapy | RR 1 [0.22, 4.56] | 1 study · 60 participants | Moderate |
Angiotensin receptor blockers (ARBs) versus angiotensin‐converting enzyme inhibitors (ACEis) for preserving residual kidney function in peritoneal dialysis patients
Population: patients receiving PD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Residual kidney function (4 weeks) Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis) | no estimate extracted | 1 study · 20 participants | Low |
Residual kidney function (12 months) Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis) | no estimate extracted | 1 study · 60 participants | Moderate |
Anuria Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis) | RR 1.15 [0.41, 3.26] | 1 study · 60 participants | Moderate |
Cardiovascular events (non‐fatal) Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis) | RR 1.33 [0.33, 5.45] | 1 study · 60 participants | Moderate |
Serum potassium Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis) | no estimate extracted | 1 study · 42 participants | Moderate |
Systolic BP Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis) | no estimate extracted | 1 study · 42 participants | Moderate |
Diastolic BP Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis) | no estimate extracted | 1 study · 42 participants | Moderate |
Cough Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis) | RR 1.56 [0.24, 10.05] | 1 study · 60 participants | Moderate |
Hyperkalaemia Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis) | RR 1.23 [0.35, 4.4] | 2 studies · 144 participants | Moderate |